Drug waste minimization as an effective strategy of cost-containment in Oncology

BMC Health Services Research

Volumn 14, Issue , 2014, Pages

  Fasola, Gianpiero ^a   Aprile, Giuseppe ^a   Marini, Luisa ^a   Follador, Alessandro ^a   Mansutti, Mauro ^a   Miscoria, Manuela ^a,b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

Author keywords

Cost containment; Drug waste; Oncology

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL PROTOCOL; COST CONTROL; DRUG COST; ECONOMICS; HUMAN; ONCOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL PROTOCOLS; COST CONTROL; DRUG COSTS; HUMANS; MEDICAL ONCOLOGY; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE);

EID: 84897652308     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-57     Document Type: Article

References (29)

1. Delivering affordable cancer care in high-income countries. Sullivan R, Peppercorn J, Sikora K, et al. Lancet Oncol 2011 12 933 980 10.1016/S1470- 2045(11)70141-3 21958503
2. Cost, coverage, and comparative effectiveness research: the critical issues for oncology. Pearson SD, J Clin Oncol 2012 30 4275 4281 10.1200/JCO.2012.42.6601 23071229
3. American Society of Clinical Oncology Statement: the cost of cancer care. Meropol NJ, Schrag D, Smith TJ, et al. J Clin Oncol 2009 27 3868 3874 10.1200/JCO.2009.23.1183 19581533
4. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. Berry SR, Bell CM, Uber PA, et al. J Clin Oncol 2010 28 4149 4153 10.1200/JCO.2010.29.1625 20697077
5. Cost of care: Tough issues facing oncology. Nierengarten MB, Lancet Oncol 2008 9 420 10.1016/S1470-2045(08)70121-9
6. Innovative cancer therapies: putting costs into context. Khayat D, Cancer 2012 118 2367 2371 10.1002/cncr.26496 21918962
7. Projecting future drug expenditures 2009. Hoffman JM, Shah ND, Vermeulen LC, et al. Am J Health Syst Pharm. 2009 66 237 257 10.2146/ajhp080636 19179637
8. Costs of cancer care: A view from the Centers for Medicare and Medicaid Services. Bach PB, J Clin Oncol 2007 25 187 190 10.1200/JCO.2006.08.6116 17210938 (Pubitemid 350003032)
9. A Model to Estimate Human Resource Needs for the Treatment of Outpatients With Cancer. Fasola G, Aprile G, Aita M, J Oncol Pract 2012 1 13 17
10. Projecting future drug expenditures 2008. Hoffman JM, Shah ND, Vermeulen LC, et al. Am J Health Syst Pharm 2008 65 234 253 10.2146/ajhp070629 18216009 (Pubitemid 351220774)
11. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia-monitoring the effect of an expensive medicine access program. Pearson SA, Ringland CL, Ward RL, J Clin Oncol 2007 25 3688 3693 10.1200/JCO.2007.11. 2516 17704417 (Pubitemid 47372608)
12. Limits on medicare's ability to control rising spending on cancer drugs. Bach PB, N Engl J Med 2009 360 626 633 10.1056/NEJMhpr0807774 19176475
13. How much is life worth: the multibillion dollar question in contemporary oncology. Fojo T, Noonan A, Grady C, Educational ASCO 2011
14. Access to cancer medications in low and middle-income countries. Lopes Gde L Jr, de Souza JA, Barrios C, Nat Rev Clin Oncol 2013 10 22 314
15. Breast cancer in Mexico: a growing challenge to health and the health system. Chávarri-Guerra Y, Villarreal-Garza C, Liedke PE, et al. Lancet Oncol 2012 13 335 e343 10.1016/S1470-2045(12)70246-2 22846838
16. International variability in the reimbursement of cancer drugs by publically funded drug programs. Cheema PK, Gavura S, Migus M, et al. Curr Oncol 2012 19 165 e176 22670106
17. Undocumented drug utilization and drug waste increase costs of pediatric anesthaesia care. Nava-Ocampo AA, Alarcón-Almanza JM, Moyao-García D, et al. Fundam Clin Pharmacol 2004 18 107 112 10.1046/j.0767-3981.2003.00214. x 14748762 (Pubitemid 38200926)
18. Implications of dose rounding of chemotherapy to the nearest vial size. Dooley MJ, Singh S, Michael M, Support Care Cancer 2004 12 653 656 14986078 (Pubitemid 39280316)
19. Drug waste minimization and cost-containment in Medical Oncology: two-years results of a feasibility study. Fasola G, Aita M, Marini L, et al. BMC Health Serv Res 2008 8 70 doi: 10.1186/1472-6963-8-70 10.1186/1472-6963-8-70 18380901 (Pubitemid 351667562)
20. Bending the cost curve in cancer care. Smith TJ, Hillner BE, N Engl J Med 2011 364 2060 2065 10.1056/NEJMsb1013826 21612477
21. Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs. Field K, Asia Pac J Clin Oncol 2010 6 203 209 10.1111/j.1743-7563.2010.01297.x 20887502
22. Cancer's next frontier: addressing high and increasing costs. Elkin EB, Bach PB, JAMA 2010 303 1086 1087 10.1001/jama.2010.283 20233828
23. Will evidence ever be sufficient to resolve the challenge of cost containment? Caplan AL, J Clin Oncol 2011 29 1946 1948 10.1200/JCO.2011.34.7039 21502551
24. The economic pressures for biosimilar drug use in cancer medicine. Cornes P, Targ Oncol 2012 7 57 S67 10.1007/s11523-011-0196-3
25. The role of generic medicines and biosimilars in oncology in low-income countries. Renner L, Nkansah FA, Dodoo AN, Ann Oncol 2013 24 Suppl 5 v32 10.1093/annonc/mdt326 23975702
26. Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings. Jarkowski A, Nestico JS, Vona KL, Khushalani NI, J Oncol Pharm Pract 2013 [Epub ahead of print]
27. Cost savings from dose rounding of biologic anticancer agents in adults. Winger BJ, Clements EA, DeYoung JL, et al. J Oncol Pharm Practice 2010 17 246 251
28. Tumour and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Ebos JML, Lee CR, Kerbel RS, Clin Cancer Res 2009 15 5020 5025 10.1158/1078-0432.CCR-09-0095 19671869
29. Affinity and avidity in antibody based tumor targeting. Rudnick SI, Adams GP, Cancer Biother Radiopharmaceut 2009 24 155 161 10.1089/cbr.2009.0627